Answers are grounded in this paper and cite their sources.
Nowadays, there is insufficient evidence for the recommendation of management patients with a primary membranoproliferative glomerulonephritis (MPGN). A better understanding of the pathogenesis has led to the reclassification of primary MPGN and distinction into the two main entities of either primary immune complex-MPGN or C3 glomerulopathy. Both entities share overlapping pathophysiological features with complement alternative pathway (AP) dysregulation. Iptacopan is an oral inhibitor of the complement factor B that effectively blocks the complement AP.
No takes yet. Share an insight, caveat, or question.
Arnold et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: